about
Diet and cancerThe potential role of podoplanin in tumour invasionAKT-ions with a TWIST between EMT and METSingle-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyGrover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.Kras in metastatic colorectal cancer.Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations.Inflammatory cytokines induce podoplanin expression at the tumor invasive front.Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.[Melanoma- finally good news].SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsSAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase ITowards More Structure: Comparing TNM Staging Completeness and Processing Time of Text-Based Reports versus Fully Segmented and Annotated PET/CT Data of Non-Small-Cell Lung CancerDetermination of the donor:host blood cell ratio after haematological stem cell transplant by means of semiquantitative detection of short tandem repeat polymorphismsPre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort studyCetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10[Stivarga shows effectiveness in practice]
P50
Q22241164-BEA168FB-38DD-46A6-859E-7B37D53E9FB1Q24653540-5D1C60B4-8BD8-4C2A-84D7-34A508B6D8DCQ28078987-C1F48025-1BB8-4773-96DD-2AB16CAADB4AQ36270828-0ABCC475-6F70-421C-A1C2-4F0524C19646Q36687229-6728EB9E-ADA0-4F40-A3BF-6BCB7CDCB5C0Q37178600-EB71A07A-D561-4E88-A37C-C16AF893A1D6Q37607383-8EC13A6B-D611-4F4A-BAEC-48188AC0E681Q37812029-44A0223D-8C11-4BCF-B2A5-65300B98CB0CQ38282771-91B2A89D-0AF3-46BE-A572-91AEE9B14306Q38302247-273B849C-634C-41AF-89AE-052DB9EAAA00Q38526844-9D61BC1E-697A-4C00-B025-0523E9C61A11Q38803420-332802AE-B91F-4242-A056-6415B992ACF2Q38824661-32F32B47-2721-4B8A-8B3B-BAA134D1BF1FQ38850036-528A2F3D-F813-42AF-B50B-9CED6EA3A6BFQ39361715-7F7E6253-409F-46CC-949F-A4739AD7336FQ39446636-030773D6-F4E7-430E-BF69-97B76D63781AQ39943000-43602D47-EB25-4378-B89E-EE39FCCFE577Q40202365-581F457A-6D92-4544-BCA3-B01815D44C13Q41378427-0D32BAE0-7A37-4C18-9285-C65B644587E2Q47608454-CF915384-25F6-4DA0-85B1-93115FCC52FAQ48906558-682AC3EE-5FC9-4D35-82E4-DDA500435C91Q49848719-396885FA-5BC7-48B9-A020-A8417DEE68C6Q50896680-583D12A3-9EC3-4100-9962-B5F345B6D8E7Q52585431-7BCDA07D-40C2-4EAD-BDCE-8141D57F23BEQ53287158-6FE7DBE6-609A-4D5D-93FA-9C954A90522CQ53332122-F8272921-427F-464B-BFFD-19865F184AE4Q54429780-E6448372-AFB5-462F-8E55-0B2DD37CCD63Q58101254-169686CE-6CA7-42C9-A497-9AA257B6F6BFQ59652447-9825E2A4-7893-4AF2-AF55-A2804A3C0F96Q59809741-3456B661-30C3-418F-B2D7-DD9F9B451807Q78321455-967F695B-92BA-4A91-8265-D1D69C65CAFDQ87933466-5431B9CA-E8FD-4E10-A0F9-595C3C75CE59Q90593938-312B8472-897C-4BF4-8577-E50F928ED8B9Q95411846-86B1BFF4-73BF-4DA2-A7E4-DE48EE3E4058
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Andreas Wicki
@ast
Andreas Wicki
@en
Andreas Wicki
@es
Andreas Wicki
@nl
Andreas Wicki
@sl
type
label
Andreas Wicki
@ast
Andreas Wicki
@en
Andreas Wicki
@es
Andreas Wicki
@nl
Andreas Wicki
@sl
prefLabel
Andreas Wicki
@ast
Andreas Wicki
@en
Andreas Wicki
@es
Andreas Wicki
@nl
Andreas Wicki
@sl
P106
P21
P214
112155284917787062852
P31
P496
0000-0002-2924-8080
P734
P735
P7859
viaf-112155284917787062852